TAMM Net client Hera BioTech has announced the first patient enrolled in an endometriosis diagnostic study!
Read Article
In this post, we are going to drill down into the second criterion and what it means. The Second Criterion - Represent breakthrough technologies; No approved or cleared alternative exist; Offer significant advantages over existing approved or cleared alternative...
Read Article
Unfortunately, yesterday the CMS (Centers for Medicare and Medicaid Services) issued a public notice delaying the effective date of the MCIT final rule for 60 days and opening a new 30-day comment period.
Read Article
In this post, we are going to drill down into the first criterion and what it means. The First Criterion: Provide for more effective treatment or diagnosis of life-threatening or irreversible debilitating human disease or conditions.
Read Article
Welcome to our blog, where we will try to clarify the obtuse announcements from FDA and CMS and cover other topics to biomedical firms. We hope you are able to take away some pearls in each of our posts. We will start with the recent FDA final guidance on Breakthrough Device Program. This will be three segments, which will segue into reimbursement and clinical trial impacts.
Read Article
On March 18, the Department of Defense (DoD), Defense Health Agency (DHA) responded to the global health crisis associated with increasing demand for ventilators with a challenge to develop low cost ventilators. This innovation challenge was launched on the Vulcan platform. Over the course of 7 days, 172 innovative ideas, two different panels of engineering and medical experts, selected 5 of the most promising designs; hence VULCAN V emerged!
Read Article